Injectable antibiotic formulations and methods of their use

FIELD: chemistry.

SUBSTANCE: group of inventions refers to chemical-pharmaceutical industry and presents a ready-to-use antimicrobial composition comprising penetamate (PNT) or a pharmaceutical equivalent thereof and at least one oily vehicle, a non-gelling, caking-inhibiting agent, wherein the composition is formulated in such a way, that the viscosity of the composition is below 3000 mPa∙s at a temperature of 20 °C, and a way of its manufacturing. Group of inventions also includes a method of treating an animal with a composition as described above, for treating or preventing mastitis, wherein the method comprises intramuscular or subcutaneous injection.

EFFECT: group of inventions allows to provide a long-term stability of the oil-based composition during storage, as well as a rapid release of the injectable active agent.

22 cl, 16 dwg, 8 tbl, 6 ex

 



 

Same patents:

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention deals with application of composition, which includes hydrolysate of pea protein and/or peptide for obtaining composition for treatment and/or prevention of infection Helicobacter pylori (versions), as well as such compositions (versions). Characterised compositions include lipid, protein and carbohydrate component, in which protein component includes protein source, which consists of pea protein hydrolysate, obtained by hydrolysis with protease, different from chymotrypsin, or from peptides, selected from group, which consists of Xaan-Asp-Phe-Leu-Glu-Asp-Ala-Phe-Asn-Val-Asn-Arg-Xaam and Xaan-Glu-Leu-Ala-Phe-Pro-Gly-Ser-Ala-Gln-Glu-Val-Asp-Arg-Xaam, where each Xaa independently can be any amino acid, and n and m are integer numbers, independently varying from 0-10, where peptide is contained in pea protein hydrolysate, or from both.

EFFECT: claimed inventions make it possible to treat or prevent diseases, caused by Helicobacter pylori infection, and/or diseases, associated with infection Helicobacter pylori in mammals.

17 cl, 2 tbl, 1 ex

FIELD: veterinary medicine.

SUBSTANCE: method comprises subcutaneous administration of antibiotic preparation enroxyl 5% at a dose of 0.1 ml/kg daily one time a day for 7 days and intramuscular administration of homeopathic preparation ovarinin at a dose of 1 ml/kg one time for 4 days, 4-fold.

EFFECT: use of the invention enables to increase the efficiency of treatment, to reduce treatment time and to restore reproductive function of dogs.

2 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine and describes pharmaceutical composition, including therapeutically effective quantity of compound, which has the following structure: , where compound in pharmaceutical composition is present in quantity, efficient for treatment or prevention of antibacterial infection in mammalian subject. Methods of obtaining and application of said dosed forms or pharmaceutical compositions are also claimed.

EFFECT: obtaining composition for treatment or prevention of antibacterial infection in mammalian subject.

15 cl, 8 tbl, 5 ex, 4 dwg

FIELD: medicine.

SUBSTANCE: group of inventions refers to veterinary science and is applicable for treating bovine mastitis. What is declared is a nosode for producing a preparation for treating bovine mastitis. That involves taking mastitis milk 1 ml with clinical signs of purulent-catarrhal mastitis, filling it 70° alcohol 9 ml to produce a homogenous solution; the produced solution is diluted to "Д6" with 70° alcohol. What is also declared is a preparation for treating bovine mastitis containing an aqueous-alcoholic solution of components. The components are Belladonna, Sulphur, Apis mellifica, Conium, Phytolacca, Silicea and above nosode in the following proportions, wt %: Belladonna - 5, Sulphur - 20, Apis mellifica - 20, Conium - 10, Phytolacca - 10, Silicea - 5, nosode - 15, aqueous-alcoholic solution up to 100%. What is also declared is a method of treating bovine mastitis involving the intracisternal administration of the preparation. The preparation is administered in a dose of 5-10 ml per 1 animal once a day.

EFFECT: declared group of inventions is highly effective in treating bovine mastitis.

3 cl, 5 tbl, 1 ex

Antimicrobial agent // 2556509

FIELD: medicine.

SUBSTANCE: compound 2-(1'-hydroxy-4'-isopropenyl-1'-methylcyclohexyl-2'-thio)-methylethanoate having structural formula I: is applicable as an antimicrobial agent.

EFFECT: using the compound of formula I possessing antimicrobial activity provides treating infectious processes caused by susceptible organisms.

5 tbl

FIELD: medicine.

SUBSTANCE: claimed group of inventions relates to field of veterinary. Claimed are: vaccine, aimed against actinobacillous pleuropneumonia, including lipopolysaccharide in complex with one or more repeats of ApxI, ApxII and ApxIII toxins, separated from bacterial culture and polymyxin to reduce symptoms of endotoxic shock, caused by lipopolysaccharide, method of obtaining such vaccine, application of polymyxin to reduce endotoxic shock symptoms when vaccine is introduced, in which polymixyn is added into vaccine in dose from 2.6 to 60 mcg/ml.

EFFECT: claimed group of inventions provides effective means and methods to reduce endotoxic shock symptoms, caused by lipopolysaccharide, when vaccine against actinobacillous pleuropneumonia is introduced to animal.

14 cl, 4 tbl, 4 ex

FIELD: veterinary medicine.

SUBSTANCE: complex antibacterial agent for animals, containing a compound from the group of fluoroquinolones and auxiliary substances, characterised in that it additionally comprises a compound from the group of pleuromutilins in an effective amount.

EFFECT: invention is effective against vegetative and spore forms of bacteria, it is harmless, has no allergenic properties, has a stimulating effect on the indices of humoral immune response, and is stable during storage.

6 cl, 9 ex

FIELD: veterinary medicine.

SUBSTANCE: agent comprises enrofloxacin and excipients. The agent additionally comprises humates of peat or sapropel, with the following ratio of the components, wt %: enrofloxacin substance - 0.5; alkaline solution of humates (pH=12-13) - 80; succinic acid - to pH 10-11; propylene glycol - the rest. The agent is administered with the liquid feed once a day for three to five days at a dose of from 0.5 to 1.0 ml per 1 kg of body weight.

EFFECT: manifestation of pronounced therapeutic effect.

5 tbl, 2 ex

FIELD: chemistry.

SUBSTANCE: invention relates to method of obtaining 7-hydroxyroyleanon, possessing antimicrobial action. said method includes extraction of crushed roots of salvia officinalis with 96% ethyl alcohol with further extract evaporation, processing with water, alcohol distillation and processing with hydrophobic solvent or extraction of said raw material with chloroform with further extract processing with water and evaporation; after which target product is extracted from organic phase by transfer into water-soluble phenolates, with processing with sodium hydroxide water solution; alkali solution is washed with chloroform; acidified with hydrochloric or sulphuric acid; obtained sediment is filtered; dried and crushed.

EFFECT: invention is characterised by improved process manufacturability and provides obtaining individual substance with higher antimicrobial activity than previously extracted royleanon derivatives from salvia officinalis.

2 tbl, 6 ex

FIELD: biotechnology.

SUBSTANCE: invention relates to a strain of the pathogen of pseudomonosis of pigs of the collection of Federal state budgetary institution "VGNKI", deposited under the name "Pseudomonas aeruginosa No.9" and the registration number "No.9-DEP", intended for production of a vaccine against pseudomonosis of pigs.

EFFECT: invention provides high immunogenic activity and the ability of production of the vaccine against pseudomonosis of pigs.

4 ex, 3 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to medicine, in particular to a pharmaceutical composition in the form of the extrudate, containing at least one pharmaceutically active substance in the form of needles, characterised by the fact that the ratio of the particle size of the needle-like active substance to the diameter of strands constitutes at least 1:25.

EFFECT: invention makes it possible to obtain the more homogeneous extrudate.

11 cl, 13 ex, 10 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to chemical-pharmaceutical industry and represents a method for reducing extracellular matrix producing cells in lungs or suppressing an increase of the extracellular matrix producing cells in lungs, involving administering into an individual a composition containing (i) a carrier containing retinoid as a targeting agent, and (ii) a pro-drug specified in a group consisting of siRNA, RNA enzyme, anti-sense nucleic acid and DNA/RNA chimeric polynucleotide, which is targeted on HSP47, and vectors expressing said siRNA, RNA enzyme, anti-sense nucleic acid and/or DNA/RNA chimeric polynucleotide.

EFFECT: invention provides using retinoic acid as a targeting agent for the drug delivery to the extracellular matrix producing cells in the lungs.

8 cl, 6 dwg, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to an agent for treating hemorrhoid, proctitis and other proctologic inflammations. The above agent represents a suppository 1,35 - 3,65 g containing diosmin 0,3 - 0,65 g, dexpanthenol 0,05 - 0,2 g, green tea extract 0,05 - 0,2 g as active substances, and emulsifier 0,0135 - 0,1825 g and fatty acid glycerides as additives.

EFFECT: agent provides the integrated antimicrobial, local analgesic, anti-inflammatory, wound healing and adaptogenic therapeutic action.

2 cl, 3 ex

FIELD: medicine.

SUBSTANCE: invention provides a stable composition for treating damages associated with herpes-virus infections in a form specified in creams and gels containing low-level trichloroacetic acid. The amount of trichloroacetic acid makes less than 6% (wt / wt) of the cream or gel.

EFFECT: extending the range of products for treating the damages associated with herpes-virus infections.

25 cl, 3 ex

FIELD: medicine.

SUBSTANCE: method for preparing a medical gel for erythrocyte and leukocyte separation involves mixing polyisobutylene, chlorinated paraffin, silicon dioxide and propylene glycol hexane dioic acid in a certain environment to prepare an end product having a density required to use the above product as the medical gel.

EFFECT: method enables separating erythrocytes and leukocytes from plasma, keeping blood plasma in its natural composition with no loss of its constituent proteins and change in the concentration of its constituent vitamins and hormones.

1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to pharmaceutics and represents a pharmaceutical composition for parenteral administration containing sub-micron particles of dosocahexaenoic acid ester dispersed in a water phase with the use of mixture of at least two surfactants specified in a) at least one fatty acid polyoxyethylene ester and b) at least one phospholipide derivative, as well as a method for preparing the above pharmaceutical composition.

EFFECT: invention provides higher pharmacological activity.

14 cl, 3 dwg, 3 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to pharmaceutics and concerns a solid pharmaceutical product, a solid composition applicable in methods for photodynamic diagnosing of cancer, pre-cancer and non-cancer conditions of the lower gastrointestinal system. The solid pharmaceutical composition and pharmaceutical product contain an active ingredient representing 5-aminolevulinic acid (5-ALA), or 5-ALA ester, or their pharmaceutically acceptable salts, as well as one or more triglycerides and one or more non-ionic emulsifiers and additionally one or more enteric coating. Further, the invention refers to a method for photodynamic diagnosing of cancer, pre-cancer and non-cancer conditions of the lower gastrointestinal tract, wherein the above solid pharmaceutical compositions and pharmaceutical products are applicable.

EFFECT: group of inventions provides the effective concentration of 5-ALA in the lower gastrointestinal tract, the homogenous distribution of 5-ALA, ease of use.

17 cl, 3 ex, 9 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to pharmaceutics and medicine, and concerns a semi-solid composition and a semi-solid pharmaceutical product applicable in photodynamic therapy (PDT) of cancer, pre-cancer and non-cancer conditions of a female reproductive system, an anus and a penis, and contain an active ingredient which represent 5-aminolevulinic acid (5-ALA) ester or its pharmaceutically acceptable salts, one or more triglycerides, one or more viscosity enhancers specified in cellulose or its derivatives, synthetic polymers, polyethylene glycols, vegetable gums, starch and starch derivatives, carrageenan, agar, gelatine, wax and waxy solid substances. Further, the invention refers to a kit for photodynamic therapy.

EFFECT: group of inventions provides stability of the composition and product at room temperature, ease of use for a patient.

19 cl, 2 dwg, 10 tbl, 5 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, particularly dermatology, namely to a film coating solution for the removal of pathological nail keratoderma, containing: 10 to 20% of urea, 8 to 12% of the film coating polymer Eudragit E100, 45 to 50% of ethanol, 1 to 5% of propylene glycol, 0.5 to 1% of diethylphthalate, and water up to 100%.

EFFECT: invention provides preparing a transparent film coating high-urea solution.

5 cl, 4 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a method for preparing a dry water-dispersed pharmaceutical composition. The method consists in dispersing an active substance in a fatty acid ester and polyoxyethylene 32 melted below 80°C, and spraying the hot dispersion onto the grain excipient in a fluid bed. Once the powder cooled down, inert excipients introducible through the digestive tract are added. The invention also refers to an oral pharmaceutical composition containing the mixture prepared by the above method.

EFFECT: invention aims at solving the problem of solubilisation and intestinal absorption of the active substances which are poorly water-soluble or water-insoluble, and cannot be salinated in the gastric juice.

16 cl, 4 dwg, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to pharmaceutical industry, namely to method of obtaining encapsulated particles of metal salts. Method of obtaining particles of metal salts encapsulated in liposoluble polymer envelope consists in the fact that metal salt, selected from the group: iron sulphate, zinc sulphate, potassium iodide or calcium chloride, is dissolved in water, obtained mixture is dispersed in sodium carboxymethylcellulose in butanol in presence of E472c and mixed, with further addition of ethanol to obtained mixture, obtained suspension is filtered and dried at room temperature, under specified conditions.

EFFECT: method makes it possible to simplify and accelerate process of obtaining microcapsules.

4 ex

Up!